Aptiom (Eslicarbazepine Acetate) Patent Expiration, LOE Window & CMS Spending
Aptiom (Eslicarbazepine Acetate) by Sumitomo America: FDA Orange Book core substance LOE 2026-04-21 (last listed 2032-08-24), 9 AB generics, $270.2M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sumitomo America |
| FDA Application & Pathway | N022416 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-04-21 |
| Last Listed Patent or Exclusivity Date | 2032-08-24 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $270.2M |
| 2024 Medicare Part D Spend | $144.1M |
| 2024 Medicaid Spend | $126.1M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 20.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.